Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells

Regenerative Medicine

Volumn 6, Issue 1, 2011, Pages 95-109

  Wang, Limin ^a   Ott, Lindsey ^b   Seshareddy, Kiran ^c   Weiss, Mark L ^c   Detamore, Michael S ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b University of Kansas   (United States)

^c KANSAS STATE UNIVERSITY   (United States)

Author keywords

differentiation; musculoskeletal; regenerative medicine; umbilical cord stroma

Indexed keywords

5' NUCLEOTIDASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN 2; CONNEXIN 32; CYTOKERATIN 19; DESMIN; DIPEPTIDYL PEPTIDASE IV; ENDOGLIN; HERMES ANTIGEN; HLA ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN C; STAGE SPECIFIC EMBRYO ANTIGEN 4; THY 1 ANTIGEN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; VIMENTIN;

BONE MARROW CELL; BONE MINERALIZATION; CARTILAGE CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL STRUCTURE; CELL TYPE; CELLULAR DISTRIBUTION; CHONDROGENESIS; CORD BLOOD STEM CELL TRANSPLANTATION; DIABETES MELLITUS; HEART CELL CULTURE; HUMAN; INTRACELLULAR SIGNALING; MESENCHYMAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; STROMA CELL; TISSUE DISTRIBUTION; TISSUE ENGINEERING; TISSUE REGENERATION; UPREGULATION; XENOTRANSPLANTATION;

ADIPOCYTES; CELL DIFFERENTIATION; CELL LINEAGE; CHONDROCYTES; HEPATOCYTES; HUMANS; MESENCHYMAL STEM CELLS; MUSCLE, SKELETAL; NEURONS; OSTEOBLASTS; STROMAL CELLS; TISSUE ENGINEERING; UMBILICAL CORD;

EID: 78650662132     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.10.98     Document Type: Review

References (135)

1. Vats A, Bielby RC, Tolley NS, Nerem R, Polak JM: Stem cells. Lancet 366(9485), 592-602 (2005).
2. Brignier AC, Gewirtz AM: Embryonic and adult stem cell therapy. J. Allergy Clin. Immunol. 125(2 Suppl. 2), S336-S344 (2010).
3. Kaufman DS, Hanson ET, Lewis RL et al.: Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 98(19), 10716-10721 (2001).
4. Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M: Insulin production by human embryonic stem cells. Diabetes 50(8), 1691-1697 (2001).
5. Green H, Easley K, Iuchi S: Marker succession during the development of keratinocytes from cultured human embryonic stem cells. Proc. Natl Acad. Sci. USA 100(26), 15625-15630 (2003).
6. Blum B, Benvenisty N: The tumorigenicity of human embryonic stem cells. Adv. Cancer Res. 100, 133-158 (2008).
7. Cai J, Li W, Su H et al.: Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. J. Biol. Chem. 285(15), 11227-11234 (2010).
8. Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent induced pluripotent stem cells. Nature 448(7151), 313-317 (2007).
9. Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858), 1917-1920 (2007).
10. Maherali N, Sridharan R, Xie W et al.: Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1(1), 55-70 (2007).
11. Wernig M, Meissner A, Foreman R et al.: In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448(7151), 318-324 (2007). (Pubitemid 47080337)
12. Di Nicola M, Carlo-Stella C, Magni M et al.: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10), 3838-3843 (2002).
13. Bartholomew A, Sturgeon C, Siatskas M et al.: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30(1), 42-48 (2002).
14. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA: Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 11(4), 377-391 (2009).
15. Quarto R, Mastrogiacomo M, Cancedda R et al.: Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med. 344(5), 385-386 (2001). (Pubitemid 32107654)
16. Marcacci M, Kon E, Moukhachev V et al.: Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng. 13(5), 947-955 (2007).
17. Mueller SM, Glowacki J: Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J. Cell Biochem. 82(4), 583-590 (2001).
18. Lee SY, Miwa M, Sakai Y et al.: In vitro multipotentiality and characterization of human unfractured traumatic hemarthrosis-derived progenitor cells: a potential cell source for tissue repair. J. Cell Physiol. 210(3), 561-566 (2007).
19. Schaffler A, Buchler C: Concise review: adipose tissue-derived stromal cells - basic and clinical implications for novel cell-based therapies. Stem Cells 25(4), 818-827 (2007).
20. Gimble JM, Katz AJ, Bunnell BA: Adipose-derived stem cells for regenerative medicine. Circ. Res. 100(9), 1249-1260 (2007).
21. Zuk PA, Zhu M, Ashjian P et al.: Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13(12), 4279-4295 (2002).
22. Nakashima M, Reddi AH: The application of bone morphogenetic proteins to dental tissue engineering. Nat. Biotechnol. 21(9), 1025-1032 (2003).
23. Sloan AJ, Waddington RJ: Dental pulp stem cells: what, where, how? Int. J. Paediatr. Dent. 19(1), 61-70 (2009).
24. Gronthos S, Brahim J, Li W et al.: Stem cell properties of human dental pulp stem cells. J. Dent. Res. 81(8), 531-535 (2002).
25. Tuan RS, Boland G, Tuli R: Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res. Ther. 5(1), 32-45 (2003).
26. Choumerianou DM, Dimitriou H, Kalmanti M: Stem cells: promises versus limitations. Tissue Eng. Part B Rev. 14(1), 53-60 (2008).
27. Secco M, Zucconi E, Vieira NM et al.: Mesenchymal stem cells from umbilical cord: do not discard the cord! Neuromuscul. Disord. 18(1), 17-18 (2008).
28. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309), 71-74 (1997).
29. Childs R, Chernoff A, Contentin N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343(11), 750-758 (2000).
30. Jones EA, English A, Henshaw K et al.: Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum. 50(3), 817-827 (2004).
31. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W: b-catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105(4), 533-545 (2001).
32. Seale P, Asakura A, Rudnicki MA: The potential of muscle stem cells. Dev. Cell 1(3), 333-342 (2001).
33. Weiss ML, Medicetty S, Bledsoe AR et al.: Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinsons disease. Stem Cells 24(3), 781-792 (2006).
34. Guilak F, Awad HA, Fermor B, Leddy HA, Gimble JM: Adipose-derived adult stem cells for cartilage tissue engineering. Biorheology 41(3-4), 389-399 (2004).
35. Dominici M, Le Blanc K, Mueller I et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315-317 (2006).
36. Karahuseyinoglu S, Cinar O, Kilic E et al.: Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 25(2), 319-331 (2007). (Pubitemid 46232786)
37. Troyer DL, Weiss ML: Whartons jelly-derived cells are a primitive stromal cell population. Stem Cells 26(3), 591-599 (2008).
38. Campard D, Lysy PA, Najimi M, Sokal EM: Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 134(3), 833-848 (2008).
39. Weiss ML, Troyer DL: Stem cells in the umbilical cord. Stem Cell Rev. 2(2), 155-162 (2006).
40. Can A, Karahuseyinoglu S: Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells 25(11), 2886-2895 (2007).
41. Ciavarella S, Dammacco F, De Matteo M, Loverro G, Silvestris F: Umbilical cord mesenchymal stem cells: role of regulatory genes in their differentiation to osteoblasts. Stem Cells Dev. 18(8), 1211-1220 (2009).
42. Cho PS, Messina DJ, Hirsh EL et al.: Immunogenicity of umbilical cord tissue derived cells. Blood 111(1), 430-438 (2008).
43. Ennis J, Götherström C, Le Blanc K, Davies JE: In vitro immunologic properties of human umbilical cord perivascular cells. Cytotherapy 10(2), 174-181 (2008).
44. Sarugaser R, Ennis J, Stanford WL, Davies JE: Isolation, propagation, and characterization of human umbilical cord perivascular cells (HUCPVCs). Methods Mol. Biol. 482, 269-279 (2009).
45. Hadidian Z, Pirie NW: The preparation and some properties of hyaluronic acid from human umbilical cord. Biochem. J. 42(2), 260-265 (1948).
46. Bowles HE, McKee RD: Ruptures of the umbilical cord with a case of intrapartum rupture or all three vessels. Calif. Med. 70(5), 422 (1949).
47. Moretti P, Hatlapatka T, Marten D et al.: Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applications. Adv. Biochem. Eng. Biotechnol. 123, 29-54 (2009).
48. Mitchell KE, Weiss ML, Mitchell BM et al.: Matrix cells from Whartons jelly form neurons and glia. Stem Cells 21(1), 50-60 (2003).
49. Kadner A, Hoerstrup SP, Tracy J et al.: Human umbilical cord cells: a new cell source for cardiovascular tissue engineering. Ann. Thorac. Surg. 74(4), S1422-S1428 (2002).
50. Chao KC, Chao KF, Fu YS, Liu SH: Islet-like clusters derived from mesenchymal stem cells in Whartons Jelly of the human umbilical cord for transplantation to control Type 1 diabetes. PLoS ONE 3(1), e1451 (2008).
51. Fong CY, Richards M, Manasi N, Biswas A, Bongso A: Comparative growth behaviour and characterization of stem cells from human Whartons jelly. Reprod. Biomed. Online 15(6), 708-718 (2007).
52. Jomura S, Uy M, Mitchell K, Dallasen R, Bode CJ, Xu Y: Potential treatment of cerebral global ischemia with Oct-4+ umbilical cord matrix cells. Stem Cells 25(1), 98-106 (2007).
53. Lund RD, Wang S, Lu B et al.: Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells 25(3), 602-611 (2007).
54. Kadner A, Zund G, Maurus C et al.: Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur. J. Cardiothorac. Surg. 25(4), 635-641 (2004). (Pubitemid 38376081)
55. Sodian R, Lueders C, Kraemer L et al.: Tissue engineering of autologous human heart valves using cryopreserved vascular umbilical cord cells. Ann. Thorac. Surg. 81(6), 2207-2216 (2006).
56. Schmidt D, Mol A, Neuenschwander S et al.: Living patches engineered from human umbilical cord derived fibroblasts and endothelial progenitor cells. Eur. J. Cardiothorac. Surg. 27(5), 795-800 (2005).
57. Schmidt D, Mol A, Odermatt B et al.: Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Tissue Eng. 12(11), 3223-3232 (2006).
58. Schmidt D, Asmis LM, Odermatt B et al.: Engineered living blood vessels: functional endothelia generated from human umbilical cord-derived progenitors. Ann. Thorac. Surg. 82(4), 1465-1471; discussion 1471 (2006).
59. Wang L, Seshareddy K, Weiss ML, Detamore MS: Effect of initial seeding density on human umbilical cord mesenchymal stromal cells for fibrocartilage tissue engineering. Tissue Eng. Part A 15(5), 1009-1017 (2009).
60. Bailey MM, Wang L, Bode CJ et al.: A comparison of human umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue engineering temporomandibular joint condylar cartilage. Tissue Eng. 13(8), 2003-2010 (2007).
61. Diao Y, Ma Q, Cui F, Zhong Y: Human umbilical cord mesenchymal stem cells: osteogenesis in vivo as seed cells for bone tissue engineering. J. Biomed. Mater. Res. A 91(1), 123-131 (2008).
62. Heifetz SA: The umbilical cord: obstetrically important lesions. Clin. Obstet. Gynecol. 39(3), 571-587 (1996).
63. Hill LM, Kislak S, Runco C: An ultrasonic view of the umbilical cord. Obstet. Gynecol. Surv. 42(2), 82-88 (1987).
64. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE: Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 23(2), 220-229 (2005).
65. Wang HS, Hung SC, Peng ST et al.: Mesenchymal stem cells in the Whartons jelly of the human umbilical cord. Stem Cells 22(7), 1330-1337 (2004).
66. Fong CY, Subramanian A, Biswas A et al.: Derivation efficiency, cell proliferation, freeze-thaw survival, stem-cell properties and differentiation of human Whartons jelly stem cells. Reprod. Biomed. Online 21(3), 391-401 (2010).
67. Nanaev AK, Kohnen G, Milovanov AP, Domogatsky SP, Kaufmann P: Stromal differentiation and architecture of the human umbilical cord. Placenta 18(1), 53-64 (1997).
68. Kobayashi K, Kubota T, Aso T: Study on myofibroblast differentiation in the stromal cells of Whartons jelly: expression and localization of a-smooth muscle actin. Early Hum. Dev. 51(3), 223-233 (1998).
69. Bongso A, Fong CY, Gauthaman K: Taking stem cells to the clinic: major challenges. J. Cell Biochem. 105(6), 1352-1360 (2008).
70. Majore I, Moretti P, Stahl F, Hass R, Kasper C: Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Rev. (2010) (Epub ahead of print).
71. Lu LL, Liu YJ, Yang SG et al.: Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91(8), 1017-1026 (2006).
72. Wu KH, Zhou B, Lu SH et al.: In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells. J. Cell Biochem. 100(3), 608-616 (2007). (Pubitemid 46180525)
73. Hoerstrup SP, Kadner A, Breymann C et al.: Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. Ann. Thorac. Surg. 74(1), 46-52; discussion 52 (2002).
74. Eblenkamp M, Aigner J, Hintermair J et al.: [Umbilical cord stromal cells (UCSC). Cells featuring osteogenic differentiation potential]. Orthopade 33(12), 1338-1345 (2004).
75. Carlin R, Davis D, Weiss M et al.: Expression of early transcription factors Oct4, Sox2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reprod. Biol. Endocrinol. 4(1), 8 (2006).
76. Wu KH, Zhou B, Yu CT et al.: Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann. Thorac. Surg. 83(4), 1491-1498 (2007).
77. Jo CH, Kim OS, Park EY et al.: Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res. 334(3), 423-433 (2008).
78. Zhang P, Luo X, Wang H: Clinical transplantation of a tissue-engineered airway. Lancet 373(9665), 718; author reply 718-719 (2009).
79. Fong CY, Chak LL, Biswas A et al.: Human Whartons jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev. (2010) (Epub ahead of print).
80. Liedtke S, Stephan M, Kogler G: Oct4 expression revisited: potential pitfalls for data misinterpretation in stem cell research. Biol. Chem. 389(7), 845-850 (2008).
81. Méndez-Ferrer S, Michurina TV, Ferraro F et al.: Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308), 829-834 (2010).
82. Baksh D, Yao R, Tuan RS: Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25(6), 1384-1392 (2007).
83. Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG: Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane. Stem Cells Dev. 19(4), 491-502 (2010).
84. Anzalone R, Lo Iacono M, Corrao S et al.: New emerging potentials for human Whartons jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev. 19(4), 423-438 (2010).
85. Fan CG, Zhang QJ, Zhou JR: Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev. (2010) (Epub ahead of print).
86. Gao J, Yao JQ, Caplan AI: Stem cells for tissue engineering of articular cartilage. Proc. Inst. Mech. Eng. 221(5), 441-450 (2007).
87. Darling EM, Athanasiou KA: Rapid phenotypic changes in passaged articular chondrocyte subpopulations. J. Orthop. Res. 23(2), 425-432 (2005).
88. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU: In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp. Cell Res. 238(1), 265-272 (1998).
89. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF: Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng. 4(4), 415-428 (1998).
90. Im GI, Jung NH, Tae SK: Chondrogenic differentiation of mesenchymal stem cells isolated from patients in late adulthood: the optimal conditions of growth factors. Tissue Eng. 12(3), 527-536 (2006).
91. Spagnoli A, Longobardi L, ORear L: Cartilage disorders: potential therapeutic use of mesenchymal stem cells. Endocr. Dev. 9, 17-30 (2005).
92. Longobardi L, ORear L, Aakula S et al.: Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-b signaling. J. Bone Miner. Res. 21(4), 626-636 (2006).
93. Wang L, Detamore MS: Insulin-like growth factor-I improves chondrogenesis of predifferentiated human umbilical cord mesenchymal stromal cells. J. Orthop. Res. 27(8), 1109-1115 (2009).
94. Naughton BA: Cells isolated from Whartons jelly of the human umbilical cord develop a cartilage phenotype when treated with TGF-b in vitro. FASEB J. 11, A19 (Abstr. No. 108) (1997).
95. Barry F, Boynton RE, Liu B, Murphy JM: Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp. Cell Res. 268(2), 189-200 (2001).
96. Pittenger MF, Mackay AM, Beck SC et al.: Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
97. Wang L, Tran I, Seshareddy K, Weiss ML, Detamore MS: A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. Tissue Eng. Part A 15(8), 2259-2266 (2009).
98. Motoki DS, Mulliken JB: The healing of bone and cartilage. Clin. Plast. Surg. 17(3), 527-544 (1990).
99. Habal MB: Bone repair by regeneration. Clin. Plast. Surg. 23(1), 93-101 (1996).
100. Salgado AJ, Coutinho OP, Reis RL: Bone tissue engineering: state of the art and future trends. Macromol. Biosci. 4(8), 743-765 (2004).
101. Martin-Rendon E, Sweeney D, Lu F, Girdlestone J, Navarrete C, Watt SM: 5-azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang. 95(2), 137-148 (2008).
102. Hou T, Xu J, Wu X et al.: Umbilical cord Whartons Jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering. Tissue Eng. Part A 15(9), 2325-2334 (2009).
103. Xu HH, Zhao L, Detamore MS, Takagi S, Chow LC: Umbilical cord stem cell seeding on fast-resorbable calcium phosphate bone cement. Tissue Eng. Part A 16(9), 2743-2753 (2010).
104. Honsawek S, Dhitiseith D, Phupong V: Effects of demineralized bone matrix on proliferation and osteogenic differentiation of mesenchymal stem cells from human umbilical cord. J. Med. Assoc. Thai. 89(Suppl. 3), S189-S195 (2006).
105. Zhang ZY, Teoh SH, Chong MS et al.: Superior osteogenic capacity for bone tissue engineering of fetal compared to perinatal and adult mesenchymal stem cells. Stem Cells 27(1), 126-131 (2009).
106. Wang L, Singh M, Bonewald LF, Detamore MS: Signalling strategies for osteogenic differentiation of human umbilical cord mesenchymal stromal cells for 3D bone tissue engineering. J. Tissue Eng. Regen. Med. 3(5), 398-404 (2009).
107. Gauthaman K, Venugopal JR, Yee FC et al.: Osteogenic differentiation of human Whartons jelly stem cells on nanofibrous substrates in vitro. Tissue Eng. Part A (2010) (Epub ahead of print).
108. Penolazzi L, Tavanti E, Vecchiatini R et al.: Encapsulation of mesenchymal stem cells from Whartons jelly in alginate microbeads. Tissue Eng. Part C Methods 16(1), 141-155 (2010).
109. Zhao L, Weir MD, Xu HH: An injectable calcium phosphate-alginate hydrogel- umbilical cord mesenchymal stem cell paste for bone tissue engineering. Biomaterials 31(25), 6502-6510 (2010).
110. Wang L, Dormer NH, Bonewald LF, Detamore MS: Osteogenic differentiation of human umbilical cord mesenchymal stromal cells in polyglycolic acid scaffolds. Tissue Eng. Part A 16(6), 1937-1948 (2010).
111. Wang L, Detamore MS: Human umbilical cord mesenchymal stromal cells in a sandwich approach for osteochondral tissue engineering. J. Tissue Eng. Regen. Med. (2010) (Epub ahead of print).
112. Dormer NH, Singh M, Wang L, Berkland CJ, Detamore MS: Osteochondral interface tissue engineering using macroscopic gradients of bioactive signals. Ann. Biomed. Eng. 38(6), 2167-2182 (2010).
113. Conconi MT, Burra P, Di Liddo R et al.: CD105+ cells from Whartons jelly show in vitro and in vivo myogenic differentiative potential. Int. J. Mol. Med. 18(6), 1089-1096 (2006).
114. Kocaefe C, Balci D, Hayta BB, Can A: Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair. Stem Cell Rev. 6(4), 512-522 (2010).
115. Vieira NM, Zucconi E, Bueno CR Jr et al.: Human multipotent mesenchymal stromal cells from distinct sources show different in vivo potential to differentiate into muscle cells when injected in dystrophic mice. Stem Cell Rev. 6(4), 560-566 (2010).
116. Patrick CW Jr: Tissue engineering strategies for adipose tissue repair. Anat. Rec. 263(4), 361-366 (2001).
117. Gomillion CT, Burg KJ: Stem cells and adipose tissue engineering. Biomaterials 27(36), 6052-6063 (2006).
118. Turner NJ, Jones HS, Davies JE, Canfield AE: Cyclic stretch-induced TGFb1/Smad signaling inhibits adipogenesis in umbilical cord progenitor cells. Biochem. Biophys. Res. Commun. 377(4), 1147-1151 (2008).
119. Karahuseyinoglu S, Kocaefe C, Balci D, Erdemli E, Can A: Functional structure of adipocytes differentiated from human umbilical cord stroma-derived stem cells. Stem Cells 26(3), 682-691 (2008).
120. Breymann C, Schmidt D, Hoerstrup SP: Umbilical cord cells as a source of cardiovascular tissue engineering. Stem Cell Rev. 2(2), 87-92 (2006).
121. Schmidt D, Hoerstrup SP: Tissue engineered heart valves based on human cells. Swiss Med. Wkly 137(Suppl. 155), 80S-85S (2007).
122. Martin JA, Hamilton BE, Sutton PD et al.: Births: final data for 2005. Natl Vital Stat. Rep. 56(6), 1-103 (2007).
123. Weiss ML, Anderson C, Medicetty S et al.: Immune properties of human umbilical cord Whartons jelly-derived cells. Stem Cells 26(11), 2865-2874 (2008).
124. Drukker M: Immunogenicity of human embryonic stem cells: can we achieve tolerance? Springer Semin. Immunopathol. 26(1-2), 201-213 (2004). (Pubitemid 40021967)
125. Drukker M, Benvenisty N: The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol. 22(3), 136-141 (2004). (Pubitemid 38230392)
126. Najar M, Raicevic G, Boufker HI et al.: Adipose-tissue-derived and Whartons jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng. Part A 16(11), 3537-3546 (2010).
127. Najar M, Raicevic G, Boufker HI et al.: Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Whartons Jelly and bone marrow sources. Cell Immunol. 264(2), 171-179 (2010).
128. Selmani Z, Naji A, Zidi I et al.: Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26(1), 212-222 (2008).
129. Patel SA, Sherman L, Munoz J, Rameshwar P: Immunological properties of mesenchymal stem cells and clinical implications. Arch. Immunol. Ther. Exp. (Warsz) 56(1), 1-8 (2008).
130. Weiss ML, Mitchell KE, Hix JE et al.: Transplantation of porcine umbilical cord matrix cells into the rat brain. Exp. Neurol. 182(2), 288-299 (2003).
131. Chen X, McClurg A, Zhou GQ, McCaigue M, Armstrong MA, Li G: Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells and the effect is partially due to the upregulated expression of B7 molecules. Stem Cells 25(2), 364-370 (2007).
132. Mannello F, Tonti GA: Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells 25(7), 1603-1609 (2007).
133. Galban CJ, Locke BR: Analysis of cell growth kinetics and substrate diffusion in a polymer scaffold. Biotechnol. Bioeng. 65(2), 121-132 (1999).
134. Seshareddy K, Troyer D, Weiss ML: Method to isolate mesenchymal-like cells from Whartons Jelly of umbilical cord. Methods Cell Biol. 86, 101-119 (2008).
135. Kim JW, Kim SY, Park SY et al.: Mesenchymal progenitor cells in the human umbilical cord. Ann. Hematol. 83(12), 733-738 (2004).